In this podcast, Dr. Debra Patt discusses trends in cancer care, including how treatments are becoming more personalized and less toxic.
In this video, Dr. Judd Moul discusses disparities in prostate cancer screening among African-American men, and the need for more research in this area.
Treatment with the TLR9 agonist CMP-001 appeared to potentially reverse resistance to immune checkpoint inhibition in patients with metastatic melanoma.
In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively.
The combination of rituximab and the BCL2 inhibitor venetoclax significantly lengthened PFS among CLL patients in the phase III MURANO trial.
In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients.
A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer.
In this video, Dr. Jean Zenklusen describes an NCI tool that enables researchers, clinicians, and patients to access an array of cancer-related data.
In this video, Dr. Douglas Fearon outlines ways that inhibiting CXCR4 may provoke an immune response to treat pancreatic and colorectal cancer.
In this video, Dr. Patricia Steeg discusses the role of the blood-tumor barrier in both development and treatment of brain metastases.
In this video, Dr. Arman Rahman explains how the OncoMasTR protein assay may help women with breast cancer avoid unnecessary chemotherapy.
Combining mitoxantrone and prednisone with adjuvant androgen deprivation therapy failed to improve overall survival over ADT alone in patients with high-risk prostate cancer.
Previous studies found calcium channel blockers could prevent pancreatic cancer, but have neglected to consider the effects of short-acting CCBs.
At AACR 2018, Dr. Aung Naing of MD Anderson presented ECHO-203, the first data on epacadostat in combination with an anti–PD-L1 inhibitor.
What are appropriate sources of stem cells for HCT in patients without an HLA-matched, related donor? Is post-transplant cyclophosphamide–based haploidentical donor transplantation appropriate for racial and ethnic minority patients with hematologic cancers? Test your knowledge with this multiquestion quiz.